Aster Capital Management’s Rapport Therapeutics RAPP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.28K Sell
38
-70
-65% -$3.02K ﹤0.01% 912
2026
Q2
$4.5K Buy
+108
New +$3.97K ﹤0.01% 734
2026
Q1
– Sell
-300
Closed -$9.1K – 1413
2025
Q4
$9.1K Buy
+300
New +$8.3K ﹤0.01% 760
2025
Q1
– Sell
-5
Closed -$89 – 1735
2024
Q4
$89 Buy
+5
New +$111 ﹤0.01% 1072

Other funds holding RAPP

Aster Capital Management's RAPP Position: Q3 2026 in Review

Aster Capital Management reduced its Rapport Therapeutics (RAPP) stake by 65% in Q3 2026, selling an estimated $3.02K and leaving 38 shares worth $1.28K. The position accounts for ﹤0.01% of the portfolio, ranked #912.

Aster Capital Management first reported a position in RAPP in Q4 2024 and has held it in 4 quarters since. The position peaked at $9.1K in Q4 2025. 169 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

  • Aster Capital Management held 38 shares of Rapport Therapeutics worth $1.28K as of Q3 2026.
  • Aster Capital Management sold 70 Rapport Therapeutics shares in Q3 2026, an estimated $3.02K.
  • Rapport Therapeutics made up ﹤0.01% of Aster Capital Management's portfolio in Q3 2026, its #912 holding.
  • Aster Capital Management first reported a position in Rapport Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Aster Capital Management's Rapport Therapeutics position peaked at $9.1K in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Aster Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.